Rising Leukemia Incidences & Growing Demand for Targeted Therapy has Propelled the Growth of the Hairy Cell Leukemia Therapeutics Market in the North America Region!
- Himanshu Patni
- July 15, 2023
- HEALTHCARE, NEWS
- Hairy Cell Leukemia Therapeutics Market, Hairy Cell Leukemia Therapeutics Market Forecast, Hairy Cell Leukemia Therapeutics Market Growth, Hairy Cell Leukemia Therapeutics Market Outlook, Hairy Cell Leukemia Therapeutics Market Share, Hairy Cell Leukemia Therapeutics Market Size, Hairy Cell Leukemia Therapeutics Market Trends
- 0 Comments
During the forecast period, North America is expected to experience substantial growth in the market for hairy cell leukemia. Among the countries in the region, the United States is leading the market due to factors such as high healthcare expenditure, extensive research and development activities, and a growing prevalence of Chronic Lymphocytic Leukemia (CLL) and hairy cell leukemia. The primary driver for the hairy cell leukemia market in the United States is the rising geriatric population. Additionally, the increasing prevalence of chronic lymphocytic leukemia is projected to raise the risk of developing hairy cell leukemia among the population. For example, according to the American Cancer Society’s 2022 data, approximately 60,650 new cases of leukemia (all types) are estimated to be diagnosed in 2022, with chronic lymphocytic leukemia (CLL) accounting for around 20,160 new cases. Additionally, about one-fourth of newly diagnosed leukemia cases are CLL. Furthermore, according to the National Organization for Rare Disorders (NORD) 2021 data, approximately 6,000 individuals are affected by hairy cell leukemia, and around 600-800 new cases are diagnosed in the United States each year. Consequently, the increasing burden of leukemia cases in the population is expected to drive the demand for effective treatments and therapies, thereby boosting market growth.
Access sample report (including graphs, charts, and figures): https://univdatos.com/report/hairy-cell-leukemia-therapeutics-market/get-a-free-sample-form.php?product_id=41540
Further, the North America Hairy Cell Leukemia Therapeutics Market is expected to grow at a strong CAGR of 5% during the forecast period (2023-20230). The market growth in the region is expected to be driven by factors such as increased pharmaceutical spending on research and development, the adoption of various business strategies, and advanced technology for developing treatments and therapies. For example, according to the 2022 data from the Organisation for Economic Co-operation and Development (OECD), the United States and Canada allocated 3.4% and 1.60% of their GDP, respectively, for research and development activities in 2021. This substantial investment in research and development by these countries stimulates company activities and supports the overall growth of the market.
FIG. 1 North America Hairy Cell Leukemia Therapeutics Market Revenue (2020-2030)- USD Mn
For a detailed analysis of the Global Hairy Cell Leukemia Therapeutics Market browse through – https://univdatos.com/report/hairy-cell-leukemia-therapeutics-market/
Based on the therapy, the market is segmented into chemotherapy, biological therapy, and others. The chemotherapy segment held a significant share of the market in 2022. Chemotherapy is often the initial treatment option for HCL patients, particularly those with symptomatic or advanced disease. The most commonly used chemotherapy regimen for HCL is a combination of purine analogs, such as cladribine or pentostatin, administered over a specific duration. These drugs are highly effective in inducing remission and have shown long-term durable responses.
By distribution channel, the market is categorized into retail pharmacy, hospital pharmacy, and online pharmacy. The online pharmacy is expected to witness higher CAGR during the forecast period which is attributed to the surge in the number of internet users, widening access to online services, and the increase in the e-prescriptions in hospitals and other healthcare settings. In addition, the spur in the initiative taken by governments as well as private entities toward e-pharmacy also drives the market growth. For instance, in August 2020, Reliance Retail Limited acquired around 60% stakes in Netmeds Marketplace Ltd. to enhance the affordability of superior quality healthcare products to consumers through online mode.
Global Hairy Cell Leukemia Therapeutics Market Segmentation
Market Insight, by Therapy
- Chemotherapy
- Biological Therapy
- Others
Market Insights, by Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
Market Insight, by Region
- North America
- U.S.
- Canada
- Rest of North America
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- North America
- China
- Japan
- India
- Rest of North America
- Rest of the World
Top Company Profiles
- F. Hoffmann-La Roche Ltd
- Janssen Global Services LLC
- Dr. Reddy’s Laboratories
- Emcure Pharmaceuticals
- Amgen Inc.
- Astex Therapeutics
- Pfizer Inc.
- AstraZeneca plc
- Incyte Corp
- Merck & Co Inc.
